SCHEMBL791867

SCHEMBL791867

CC(=O)Cn1c(C)c(C)c2ccc(C)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.41
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
ABCC4 O15439 1/20 0.39
PKM P14618 1/20 0.39
PTGS1 P23219 1/20 0.39
KMT2A Q03164 1/20 0.39
ADORA1 P30542 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 2/20 0.37
KDM4E B2RXH2 2/20 0.37
NFKB1 P19838 1/20 0.37
BLM P54132 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 2/20 0.37
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
FABP4 P15090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792417 0.78 ADORA1 (0.49) PTGDR2LMNAMEN1ABCC4PKM
SCHEMBL792161 0.73 MEN1 (0.49) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL14448728 0.69 ALDH1A1 (0.62) LMNAMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL11791642 0.63 MEN1 (0.54) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL11493070 0.62 ADORA1 (0.53) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL25899951 0.61 KMT2A (0.68) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL11556498 0.61 KMT2A (0.43) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL13168788 0.60 KMT2A (0.42) PTGDR2LMNAMEN1ABCC4PKM
SCHEMBL11495935 0.59 ADORA1 (0.50) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL14817409 0.58 MEN1 (0.53) LMNAMEN1ABCC4PKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 PTGDR2 4522/4885LMNA 4323/4885MEN1 4753/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PTGDR2 4522/4885LMNA 4323/4885MEN1 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.